Kiromic Biopharma, INC S-1 registration statements
Registration statements, filed ahead of a public offering, with the business description and financials a first-time investor sees.
Kiromic Biopharma is seeking to raise capital through a unit offering to fund clinical development and working capital, contingent on listing its stock and warrants on the NYSE American.
Kiromic BioPharma is seeking to raise capital through a public offering of units, each consisting of one share of common stock and a warrant, to further its development of allogeneic Gamma Delta T-cell therapies for solid tumors.